Biomedical Research Foundation Academy Of AthensAcademy Of Athens
Scientific Personnel

Evangelos Evangelos Andreakos, PhD
Investigator - Associate Professor Level

Telephone : +30 210 6597 338
Fax : +30 210 6597 348
e-mail : vandreakos@bioacademy.gr


Center :

Clinical, Experimental Surgery & Translational Research

Lab Site :

Andreakos Lab


Brief Bio

Dr Evangelos Andreakos received his PhD in Immunology from Imperial College London under the supervision of Marc Feldmann. He worked on the role of the NF-B pathway in the regulation of immune responses during chronic inflammation and identified critical rate-limiting steps controlling macrophage and dendritic cell function (AJRCCM 2002; Blood 2003; Arthritis Rheum 2004: PNAS 2004). He then pursued his postdoctoral studies in the laboratory of Brian Foxwell by studying Toll-like receptor signaling in human systems and by investigating their role in the persistence of inflammation in rheumatoid arthritis (Blood 2004; Immunol Rev 2004; J Immunol 2007). In parallel, he developed a new approach to enhance immunogenicity of genetic vaccines through the incorporation of intracellular NF-kB activators (PNAS 2006). Intellectual property generated during this later project formed part of Synovis Ltd, a spin-off company of Imperial College London.

In 2005, Dr Andreakos became an Investigator at the Centre for Immunology and Transplantation of the Biomedical Research Foundation of the Academy of Athens. In 2006 he took up a tenure-track position as Assistant Professor (Investigator Level C’) and was promoted to Associate Professor in 2013. His studies are currently focusing on the role of innate immunity in the instruction of adaptive responses in the airways and the development and persistence of inflammation. Specific topics of interest include the function of the type III interferon system and the TLR7 pathway (AJRCCM 2010; EMBO Mol Med 2011; EMBO Mol Med 2013). Another direction of the laboratory involves the investigation of innate immune mechanisms in atherosclerosis, and their contribution to the development and vulnerability of atherosclerotic lesions (Circulation 2012). Finally, the laboratory is interested in the development of innovative technologies with translational potential for the effective delivery of oligonucleotides or small molecules to immune cells and inflammatory sites (Arthritis Rheum 2009). This work offers the prospect of identifying critical rate-limiting steps involved in inflammatory disease pathogenesis and developing innovative new strategies for therapeutic intervention.

Dr Andreakos has been the co-author of 44 articles in peer-reviewed journals and 4 book chapters. He has been invited to talk to international conferences and has given consultancy lectures to the pharmaceutical companies Abbott Laboratories (MA, USA) and Pharmacia/Pfizer (IL, USA). He is a member of various professional organizations and he is a regular reviewer for various journals including Blood, EMBO Mol Med, J Immunol, AJRCCM and AJRCMB. His work is funded by competitive grants from the European Union, the Hellenic Ministry of Education, the biotech industry and charities.

Selected Publications

Koltsida O, Karamnov S, Pyrillou K, Vickery T, Chairakaki AD, Tamvakopoulos C, Sideras P, Serhan CN, Andreakos E. Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. EMBO Mol Med 2013 Apr 15. doi: 10.1002/emmm.201201891. [Epub ahead of print]

Salagianni M, Galani IE, Lundberg AM, Davos CH, Varela A, Gavriil A, Lyytikäinen LP, Lehtimäki T, Sigala F, Folkersen L, Gorgoulis V, Lenglet S, Montecucco F, Mach F, Hedin U, Hansson GK, Monaco C, Andreakos E. Toll-Like Receptor 7 Protects from Atherosclerosis by Constraining ‘Inflammatory’ Macrophage Activation. Circulation 2012;126(8):952-62

Activin-a overexpression in the murine lung causes pathology that simulates acute respiratory distress syndrome. Apostolou E, Stavropoulos A, Sountoulidis A, Xirakia C, Giaglis S, Protopapadakis E, Ritis K, Mentzelopoulos S, Pasternack A, Foster M, Ritvos O, Tzelepis GE, Andreakos E, Sideras P. Am J Respir Crit Care Med 2012 Feb 15;185(4):382-91.

Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Übel C, Kotenko SV, Sideras P, Lehr HA, Tepe M, Klucher KM, Doyle SE, Neurath MF, Finotto S and Andreakos E. IL-28A(IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease . EMBO Mol Med 2011;3(6):348-61

Xirakia C, Koltsida O, Thanassopoulou A, Aidinis V, Sideras P, Andreakos E. Toll-like receptor 7-triggered immune response in the lung mediates acute and long-lasting suppression of experimental asthma. Am J Respir Crit Care Med 2010;181(11):1207-16

Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, Wendisch V, Benahmed AS, Giaglis S, Karras J, Lee S, Gaus H, Bennett CF, Williams RO, Sideras P, Panzner S. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum. 2009;60(4):994-1005

Andreakos E, Sacre M, Kiriakidis S, Amjadi P, Lundberg A, Giddins G, Feldmann M, Brennan F, Foxwell BM. The Toll-like receptor adaptor proteins MyD88 and Mal/TIRAP contribute to the inflammatory and destructive processes in a human model of rheumatoid arthritis. Am J Pathol. 2007;170(2):518-25

Andreakos E, Williams RΟ, Wales J, Foxwell BΜ and Feldmann M. Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant. Proc Natl Acad Sci USA 2006;103(39):14459-64

Andreakos E, Foxwell BM and Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004;202:250-65

Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, Cheshire N, Paleolog E, Feldmann M. Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis. Proc Natl Acad Sci USA 2004;101(15):5634-9

Andreakos E, Sacre S, Smith C, Lundberg A, Kiriakidis S, Stonehouse T, Monaco C, Feldmann M and Foxwell BM. Distinct pathways of LPS-induced NF-kappa B activation and cytokine production in human myeloid and nonmyeloid cells defined by selective utilization of MyD88 and Mal/TIRAP. Blood 2004;103(6):2229-37

Andreakos E, Smith C, Monaco C, Foxwell BM, Brennan FM and Feldmann M. Ikappa B kinase 2 but not NF-kappa B-inducing kinase is essential for effective DC antigen presentation in the allogeneic mixed lymphocyte reaction. Blood 2003;101(3):983-991.

PubMed:

PubMed Link